| Literature DB >> 15639052 |
Johannes W J Bijlsma1, Kenneth G Saag, Frank Buttgereit, José A P da Silva.
Abstract
Recent evidence for a disease-modifying potential of low-dose glucocorticoids (GCs) in the treatment of rheumatoid arthritis has renewed the debate on the risk benefit ratio with this therapy. Two recent developments are described that might have a positive influence on these risk benefit ratios. One is the improvement in new GC compounds--designer GCs, alterations in bioactivity, and alterations in formulations. The other is a better understanding and management of the toxicity of GCs.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15639052 DOI： 10.1016/j.rdc.2004.10.003
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN： 0889-857X Impact factor: 2.670